Editas will earn an upfront payment of $25 million to launch three research programs to apply CRISPR/Cas9 and TALEN genome editing to Juno's immunotherapies.
Ventana will develop an in vitro companion diagnostic assay to identify high levels of hyaluronan in metastatic pancreatic cancer patients.
The firm is pursuing CE-IVD clearance of the new platform populated with a menu of its MGB assays.
The companies' first offering is expected to be a multiplex respiratory disease panel.
The partners will work on capturing circulating tumor cells for whole-genome sequencing and for use in mouse models for drug discovery and biomarker development.
In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.
Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.
A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.
In PNAS this week: co-evolutionary signatures of insect hosts and bacterial symbionts, distinct transcript isoforms of high-grade ovarian cancer, and more.